HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Kura Oncology (NASDAQ:KURA) and maintained a price target of $32.
December 08, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on Kura Oncology with a $32 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst typically instills confidence in investors and can lead to a positive short term impact on the stock price. The specific mention of Kura Oncology and the maintained price target suggest a strong endorsement of the company's value and potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100